SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-20-023471
Filing Date
2020-08-24
Accepted
2020-08-24 16:09:19
Documents
6
Period of Report
2020-08-17
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 8-K ea125914-8ka_kintara.htm 8-K/A 22473
2 INDEPENDENT AUDITOR'S CONSENT ea125914ex23-1_kintara.htm EX-23.1 2501
3 CONSOLIDATED FINANCIAL STATEMENTS OF ADGERO AS OF DECEMBER 31, 2019 AND 2018, AN ea125914ex99-1_kintara.htm EX-99.1 161049
4 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ADGERO AS OF MARCH 31, ea125914ex99-2_kintara.htm EX-99.2 164284
5 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, ea125914ex99-3_kintara.htm EX-99.3 182215
6 GRAPHIC ex99-2_001.jpg GRAPHIC 4276
  Complete submission text file 0001213900-20-023471.txt   539810
Mailing Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130
Business Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K/A | Act: 34 | File No.: 001-37823 | Film No.: 201127984
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences